Video

Dr. Burke on the Underrepresentation of Elderly Patients in Clinical Trials for Lymphoma

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

John M. Burke, MD, blood cancer specialist, Rocky Mountain Cancer Center, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Due to the inability to tolerate some treatments, older patients tend to be excluded more frequently from clinical trials across all cancer types, Burke says. Additionally, when drugs are being developed, extended survival is a key component to demonstrating benefit, and older patients have a naturally shorter lifespan than younger patients, Burke explains.

Survival can also be influenced by comorbidities in elderly patients, affecting a patient’s ability to tolerate adverse effects, Burke continues. For example, an elderly patient may have a higher risk of underlying cardiac or kidney disease, leading to poor tolerance and increased toxicities, Burke explains. The risks of comorbidities impacting a drug’s effectiveness lead to elderly patients being excluded from clinical trials, Burke concludes.

Related Videos
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center